European Healthtech Grabs The Investor Headlines In H1 2022

Cautious Optimism For Sector And M&A Set To Stay Strong In 2022

After a runaway 2021 and a strong if bumpy Q1 2022, all health care product sectors underwent an investment dip in Q2, says Silicon Valley Bank. Healthtech in Europe remained a stand-out performer.

Shutterstock

Investment activity in biopharma, healthtech, diagnostics and tools and medtech in the first half of 2022 had to be assessed against the backdrop of a volatile macro and economic environment. While Q1 remained very strong in an uncertain market, in Q2, on the public market side, the ride got more bumpy. This led to a dip in investment in all four subsectors, compared with Q1.

That was the overall assessment of the market from Silicon Valley Bank’s Sophie Ehrlich, a London-based healthtech banker heading up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Market Intelligence

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.